CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2017—NanoMolecularDX announced it has acquired the assets of Nuclea Biotechnologies. Assets include all of the intellectual property, biological material, capital equipment, licenses, FDA approvals and allowances, marketing and customer materials, trademarks, and all relevant scientific data. NMDX began selling in May HER2/neu blood testing kits acquired from Nuclea.
NMDX also announced it signed distribution agreements, effective in June, with Martell Diagnostic Laboratories and Immuno-Biological Laboratories. Martell will perform biological testing of certain patient serum samples provided by NMDX at Martell’s CLIA-certified laboratory. Martell will purchase HER2 assay kits from NMDX for its own projects and for clinical testing of NMDX patient samples.
IBL-America has been granted a nonexclusive right to sell NMDX’s products, including the IVD HER2/neu ELISA and selected antibodies, as well as any other products at the discretion of NMDX, according to the company.
NMDX, 413-650-5838